BRIEF—Oxford Genetics to work with CGT Catapult in UK

Oxford Genetics has launched a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult), a UK Government-funded industry accelerator.

The project is aimed at developing scalable Lentiviral manufacturing processes, ultimately with the goal of enabling the development of existing and novel therapies in a more scalable and efficient way.

Oxford Genetics chief scientific officer Tom Payne said: “Recent clinical outcomes, notably relating to autologous CAR-T therapies, are driving the demand for a robust, scalable, and cost-efficient manufacturing process for Lentiviral vectors.”

“This collaboration will facilitate generating process datasets and scale-up approaches using Oxford Genetics proprietary technologies,” he added.